8-K: Wrap Technologies Files Series B Preferred Stock Designation

Wrap Technologies, Inc. has officially filed the Certificate of Designations for its newly created Series B Convertible Preferred Stock, detailing the terms of a private placement.

Summary

• Filed the Certificate of Designations of Series B Convertible Preferred Stock with the Secretary of State of Delaware on August 20, 2025, making it effective.
• This action follows a Securities Purchase Agreement entered into on August 18, 2025, with certain accredited investors.
• The private placement involves the sale of 4,500 shares of Series B Convertible Preferred Stock, each with a par value of $0.0001 and a stated value of $1,000.
• The Series B Preferred Stock is initially convertible into up to 3,000,000 shares of common stock at an initial conversion price of $1.50 per share.
• Accompanying warrants were issued to purchase up to 3,000,000 shares of common stock, with an initial exercise price of $1.50 per share.
• Both the conversion of preferred stock and the exercise of warrants are subject to obtaining requisite stockholder approval.
• Holders of Series B Preferred Stock are entitled to receive dividends as declared by the Board of Directors, payable in cash, securities, or assets.
• Upon liquidation, holders are entitled to receive an amount equal to the stated value plus any declared, accrued, and unpaid dividends before any distribution to holders of junior securities.
• The Series B Preferred Stock has limited voting rights, primarily requiring affirmative vote for adverse changes to its preferences, charter documents, or an increase in authorized preferred shares.
• A beneficial ownership limitation restricts conversion to prevent any holder (with affiliates) from beneficially owning in excess of 4.99% or 9.99% of the outstanding common stock, adjustable by the holder.
• Issuance limitations are in place to comply with Trading Market rules if stockholder approval is not obtained, restricting the number of common shares issued upon conversion or warrant exercise.

Sentiment

Score: 6

Explanation: The filing is a procedural update on a previously announced capital raise. While the capital raise itself is positive for funding, the filing itself is neutral as it merely formalizes the terms. The potential for future dilution and the need for stockholder approval introduce some uncertainty.

Positives

• Formalizes the terms of a capital raise through a private placement, providing funding for the company.
• The Series B Preferred Stock includes liquidation preferences, offering a degree of protection to the new investors.
• The structure with convertible preferred stock and warrants allows for future equity conversion, providing upside potential for investors while deferring immediate dilution for common shareholders until stockholder approval.

Negatives

• The potential for significant future dilution exists for current common stockholders if the preferred stock is converted and warrants are exercised, totaling up to 6,000,000 new common shares.
• Conversion of preferred stock and exercise of warrants are contingent on obtaining requisite stockholder approval, introducing an element of uncertainty regarding the full execution of the financing terms.
• The beneficial ownership limitation may restrict the immediate full conversion by large investors, potentially affecting liquidity for those holders.

Risks

• Dilution Risk: The potential issuance of up to 3,000,000 common shares from preferred stock conversion and 3,000,000 common shares from warrant exercise could significantly dilute the ownership percentage of existing common stockholders.
• Stockholder Approval Risk: The conversion of Series B Preferred Stock and the exercise of accompanying warrants are contingent upon obtaining requisite stockholder approval, which is not guaranteed and could delay or prevent full realization of the financing's terms.
• Regulatory Compliance Risk: Issuance limitations are in place to avoid breaching Trading Market rules if stockholder approval is not obtained, which could impact the company's ability to fully utilize the financing structure.
• Market Price Volatility: The conversion price and warrant exercise price of $1.50 per share could be impacted by fluctuations in the common stock's market price, affecting the value proposition for both the company and investors.

Future Outlook

The conversion of Series B Preferred Stock and exercise of accompanying warrants are contingent upon obtaining requisite stockholder approval, which will enable the full realization of the capital raise and potential dilution. The company will also need to file a registration statement for the resale of underlying shares.

Management Comments

• Scot Cohen, Chief Executive Officer, signed the Form 8-K on behalf of Wrap Technologies, Inc.

Industry Context

This private placement of convertible preferred stock and warrants is a common financing strategy for growth-oriented companies, particularly those in the technology or security sectors, to raise capital without immediate significant dilution, while providing investors with potential upside through equity conversion. It allows companies to secure funding for operations or strategic initiatives.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Face potential dilution upon conversion of preferred stock and exercise of warrants. Their voting power could be affected by the new preferred stock's limited voting rights on specific matters.
• Series B Investors: Gain a senior security with liquidation preference and potential for equity upside through conversion, subject to stockholder approval. They also have specific protections regarding adverse changes to their rights.
• Company: Secures capital for operations and strategic initiatives, but must manage the process of obtaining stockholder approval and potential future dilution.

Next Steps

• Obtain requisite stockholder approval for the conversion of Series B Preferred Stock and exercise of warrants.
• File a Registration Statement to cover the resale of underlying shares by holders, as per the Registration Rights Agreement.

Key Dates

Recommendation

The filing is a procedural step following a previously announced capital raise. While the capital infusion is generally positive for the company's financial position, the potential for significant future dilution from the conversion of preferred stock and exercise of warrants, coupled with the contingency of stockholder approval, creates uncertainty. Investors should hold and monitor the outcome of the stockholder vote and the company's use of proceeds before making further investment decisions.

Keywords

Wrap Technologies, WRAP, Series B Preferred Stock, Convertible Preferred Stock, Private Placement, Warrants, SEC Filing, 8-K, Capital Raise, Stockholder Approval, Dilution, Corporate Governance